U.K. & Canada appear to be using AH1N1 vaccines with adjuvant squalene

[Guest guest]

U.K. & Canada appear to be using AH1N1 vaccines with adjuvant

squalene

(this is what it looks like to me - anyone else?)

Sheri

http://www.healthfreedomusa.org/?p=3582,

Baxter and Novartis’ adjuvant of choice is called MF59, detailed in the

article below as a powerful – and highly toxic – squalene compound.

GSK’s adjuvant, MLP(AS04) [also identified as AS03 in company statements

and, like AS01 and 2, contains MLP, or, in simple terms, squalene] is

also a powerful and literally poisonous auto immune stimulant made from

squalene.

http://www.theflucase.com/index.php?option=com_content & view=article & id=425%3Amillion-times-more-squalene-in-swine-flu-jab-than-caused-the-gulf-war-syndrome & catid=41%3Ahighlighted-news & Itemid=105 & lang=en

Million TIMES More Squalene In H1N1 Vax Than Caused GWI

!!

http://www.examiner.com/x-10438-Peace-Studies-Examiner~y2009m8d16-H1N1-vaccine-biological-weapon-of-mass-destruction-human-experimentation

According to Meryl Nass, M.D, an authority on the anthrax vaccine,.

" A novel feature of the 2 H1N1 vaccines being developed by

corporations Novartis and GlaxoKline is the addition of

squalene-containing adjuvants to boost immunogenicity and significantly

cut back the amount of viral antigen required. This interprets to quicker

production of desired vaccine quantities. " MF59 still has to be

licensed by the FDA to be used in any US vaccine, regardless of its

history of use in other nations.

So Canada is getting the

GlaxoKline version with AS04

adjuvant (squalene) (except I guess pregnant women won't get the

adjuvanted one)

Same one as in UK approved today and same one that will probably be the

5th one used in the US

Sheri

http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20090925/vaccine_orders_090925/20090925?hub=Health

Feds order more vaccine for pregnant women,

childrenUpdated Fri. Sep. 25

2009 3:24 PM ET

The Canadian Press

OTTAWA -- Canada has ordered more swine-flu vaccine for pregnant women

and children.

The country's chief public health officer, Dr. -, says

1.8 million doses of unadjuvanted pandemic vaccine have been ordered.

That's up from the original order of 1.2 million doses from

GlaxoKline, Canada's pandemic vaccine manufacturer.

The unadjuvanted vaccine is reserved for pregnant women, who are at

significantly greater risk of becoming severely ill and dying if they

contract the virus, and children under three years old.

There are no data on the use of adjuvanted flu vaccine in pregnant women

-- a fact that may add to the already-high degree of reluctance many

pregnant women feel about taking any medication or therapy.

Adjuvants are compounds that boost the immune system's response to

vaccine, allowing smaller doses to be used per person.

The government has also ordered some 50 million doses of adjuvanted

vaccine for everyone else.

************

It is hard to find this in one place -- no package insert evident

yet

GSK's proprietary adjuvant system AS03, (same same as used in Cervarix

hpv vax) (squalene-based oil-in-water emulsion)

NOTE: The adjuvant is added to the antigen vial at the

time of dispensing for immunisation.

The medical professional adds the adjuvant

two single doses at least 3 weeks apart.

PROBABLY.............................

besides the antigens, Triton X-100 ingredients, tocopheryl hydrogen

succinate, Tween 80

we've seen those nasties before

plus hydrocortisone, gentamycin, ovalbumin, formaldehyde, sodium

deoxycholate

PROBABLY

single - dose - no thimerosal

multi-dose vials - 5 mcg per dose (except for if bottle not shaken well,

those getting the doses at the bottom of the bottle will get even

more)

http://tucksolutions.com/blog/tag/pandemic/

GSK’s Pandemrix is a split-virion inactivated vaccine, produced in

embryonated hens eggs. Split-virion vaccines contain virus that

has been disrupted with detergent, and purified by centrifugation and

diafiltration. The virus is inactivated with formaldehyde and sodium

deoxycholate. In contrast to Celvapan, which contains no adjuvant,

Pandemrix contains the adjuvant AS03, a squalene based oil-in-water

emulsion. The vaccine is supplied in a two-vial format, one containing

the antigen, the other the adjuvant. The adjuvant is added to the

antigen vial at the time of dispensing for immunisation. The

vaccine antigen is produced in Dresden, Germany.

*************

http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10089.htm

Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’

vaccine receives positive opinion from European

RegulatorsGlaxoKline (GSK) announced today that the

European Committee for Medicinal Products for Human Use (CHMP) has issued

a positive opinion and recommends approval of GSK’s candidate pandemic

(H1N1) adjuvanted vaccine Pandemrix™.

Issued: Friday 25 September 2009, London UK

GlaxoKline (GSK) announced today that the European Committee for

Medicinal Products for Human Use (CHMP) has issued a positive opinion and

recommends approval of GSK’s candidate pandemic (H1N1) adjuvanted vaccine

Pandemrix™. The indication for the vaccine is for protection

against pandemic H1N1 2009 influenza.

Each single dose of the vaccine will comprise 3.75ug antigen of pandemic

(H1N1) 2009 influenza strain and GSK's proprietary adjuvant system AS03,

which should be administered as two single doses at least 3 weeks apart.

“This positive opinion means that Pandemrix will now be

immediately reviewed for approval by the European Commission which is an

important step closer to helping reduce the impact of the pandemic.

GSK will continue to work closely with regulators, governments and health

authorities around the world so that they can determine the most

appropriate strategy to address the H1N1 pandemic,” said Stéphenne,

President GlaxoKline Biologicals.

The positive opinion is based on the ‘mock-up’ Pandemrix

registration file using the H5N1 antigen which was approved in Europe in

May 2008. The file included data from numerous clinical and pre-clinical

trials which evaluated tolerability, reactogenicity, immunogenicity and

cross-protection. The H5N1 vaccine was shown to be generally well

tolerated and the most commonly reported side effects were headache,

arthralgia (joint pain), myalgia (muscle pain), reactions at the site of

the injection (pain and redness), fever and fatigue (tiredness).

Initial information collected on the tolerability and effectiveness of

the vaccine using the H1N1 antigen were also submitted to the CHMP for

evaluation. These included recently announced results from the first

clinical trial assessing use of the pandemic (H1N1) adjuvanted vaccine,

which demonstrated, that after one dose, the vaccine can provide a strong

immune response which exceeds the immunogenicity criteria as defined by

international licensing authorities for a pandemic influenza vaccine. The

initial tolerability data after the first dose of the H1N1 vaccine

indicate a similar tolerability profile as was seen in H5N1 vaccine

clinical trials.

GSK is conducting 16 clinical trials in over 9000 subjects including

healthy adults, the elderly and children (including infants) across

Europe, Canada and the US to further evaluate its pandemic (H1N1)

adjuvanted vaccine.

All the data from this clinical development programme will be submitted

to the regulators as soon as they are available and they will also be

posted on GSK’s Clinical Study Register.

GSK supports the WHO’s call for post-marketing surveillance of the

‘highest possible quality’ to ensure extensive safety evaluation of all

pandemic vaccines. When governments commence vaccination

programmes, GSK will collect information on the safety of the vaccine

while it is being used. In addition, the Company will undertake a

large 9000 people post-marketing safety and effectiveness study.

************

http://justthevax.blogspot.com/2009/09/20092010-h1n1-vaccines-for-us.html

GSK's Monovalent H1N1

Injectable: The The 2009 Monovalent H1N1 Vaccine is an inactivated

split-virion vaccine (most likely) manufactured on the same platform as

their

Pandemrix vaccine, which incorporates the same manufacturing process

as

Fluarix.

GSK H1N1 vaccine is a split-virion influenza vaccine that will probably

be formulated to contain 15 mcg hemagglutinin (HA) per 0.5-mL dose of the

following virus strain: A/California/7/2009 (H1N1)v-like virus. The virus

is propagated in fertilised hens’ eggs. Each 0.5-mL dose also contains

0.120 mg octoxynol-10 (TRITON® X-100), 0.1 mg -tocopheryl hydrogen

succinate, and 0.380 mg polysorbate 80 (Tween 80).

Each dose may also contain residual ( 0.0016 mcg) amounts of

hydrocortisone, 0.15 mcg gentamicin sulfate, 1 mcg ovalbumin, 50 mcg

formaldehyde, and 50 mcg sodium deoxycholate from the manufacturing

process. It should be available in 0.5 mL single-dose, pre-filled

syringes and contains no preservative (thimerosal). It may also be

available in 5 mL multi-dose vials containing ten doses. Thimerosal (an

ethylmercury derivative), is added as a preservative and each 0.5 mL dose

contains 5 mcg (micrograms) of ethylmercury.

Indications and Usage: GSK H1N1 Monovalent Vaccine is indicated

for active immunization of adults (18 years of age and older) against

influenza disease caused by pandemic (H1N1) 2009 virus. Adults 18 years

of age and older should receive a single 0.5 mL intramuscular dose.

****************

The European Medicines Agency (EMEA) has

approved GlaxoKline's

"

Pandemrix "

Sheri Nakken, R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://www.nccn.net/~wwithin/vaccine.htm or

http://www.wellwithin1.com/vaccine.htm

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start September 30 & October

1

http://www.wellwithin1.com/vaccineclass.htm or

http://www.wellwithin1.com/homeo.htm